BRCA1/2 Mutation Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Malignant ovarian lesions can form as primary lesions from the ovary's healthy tissues or as secondary lesions from tumors that have metastasized to other parts of the body. Examples of primary lesions include sex-cord stromal tumors, germ-cell tumors, epithelial ovarian carcinoma, which makes up 70% of all ovarian malignancies, and other, less common types. According to the American Cancer Society, 19,88 new cases of ovarian cancer are anticipated to be discovered in 2022, and 12,810 people are anticipated to die from the disease. Although it is the 18th most common cancer in women, ovarian cancer is the fifth most common cause of cancer mortality in women, accounting for 5% of cancer fatalities, more than any other gynecologic cancer. The rising incidence of ovarian cancers with BRCA mutations worldwide is anticipated to drive the market for ovarian cancers that have these mutations. Advanced and early genetic testing for BRCA mutations in the general population will drive the BRCA mutation-positive ovarian cancer market.

Description

Malignant ovarian lesions can form as primary lesions from the ovary's healthy tissues or as secondary lesions from tumors that have metastasized to other parts of the body. Primary lesions include germ-cell tumors, sex-cord stromal tumors, and other uncommon types. Epithelial ovarian carcinoma, which makes up 70% of all ovarian malignancies, is an example. The endometrium, breast, colon, stomach, and cervix are the most frequently encountered sites for metastases, and metastases to the ovaries are common. Despite the fact that ovarian cancers can have a variety of histologic subtypes, epithelial tumors make up more than 90% of these cancers. Many of them originate from the fallopian tubes, in reality.

BRCA1/2 Mutation Ovarian Cancer (Epidemiology)

The American Cancer Society has stated that in 2022 there will be 19,88 new cases of ovarian cancer and 12,810 cases of the disease that will result in death. Despite being the 18th most common cancer in women, ovarian cancer is the fifth most common cause of cancer mortality in women, accounting for 5% of cancer fatalities, more than any other gynecologic cancer. At some point in their lives, 1 in 202 women in the general population will develop ovarian cancer. But by the time they are 70 to 80 years old, ovarian cancer will have spread to between 11 and 7% of women who inherit a risky BRCA2 variant and between 39 and 44% of women who inherit a harmful BRCA1 variant. Only 20% of cases of the disease, or in stages I or II, are found early, according to the National Ovarian Cancer Coalition. If the disease is found in stages III or above, the survival rate may be as low as 30%.

BRCA1/2 Mutation Ovarian Cancer -Current Market Size & Forecast Trends

The market for BRCA1/2 mutation ovarian cancer treatment is projected to experience significant growth, reaching approximately USD 10.2 billion by 2032, with a compound annual growth rate (CAGR) of 7.47% from 2024 to 2032. This growth is driven by the increasing prevalence of BRCA mutations among ovarian cancer patients, advancements in genetic testing technologies such as next-generation sequencing, and the rising adoption of targeted therapies like PARP inhibitors, which have shown efficacy in treating BRCA-mutated ovarian cancers. Additionally, the overall BRCA mutations treatment market is expected to reach USD 7.2 billion by 2032, indicating a robust demand for innovative therapies and diagnostic solutions. As awareness of genetic testing increases and more patients are identified as eligible for targeted treatments, the market is anticipated to expand further through 2035.

The market for ovarian cancers with BRCA mutations is anticipated to be driven by the increasing incidence of ovarian cancers with BRCA mutations around the world. Advanced and early genetic testing for BRCA mutations in the general population will drive the BRCA mutation-positive ovarian cancer market. The market for BRCA mutation-positive ovarian cancer may, however, be constrained in the future by high genetic testing costs and a lack of geneticists. The market for ovarian cancer with a BRCA mutation is expected to grow quickly over the course of the projected period due to an increase in female cases of ovarian cancer. Because cutting-edge therapies will soon be created for the condition, the market for ovarian cancer with a BRCA mutation has a lot of potential. With novel treatment options like Pidnarulex (Senhwa Biosciences), Alpelisib (Novartis Oncology), Avelumab (Merck KGaA), and others, numerous pharmaceutical companies have entered the BRCA1/2 Mutation Ovarian Cancer market to compete. These treatments have the potential to drive the market for BRCA1/2 Mutation Ovarian Cancer in an upward trend.

Report Highlights

BRCA1/2 Mutation Ovarian Cancer - Current Market Trends

BRCA1/2 Mutation Ovarian Cancer - Current & Forecasted Cases across the G8 Countries

BRCA1/2 Mutation Ovarian Cancer - Market Opportunities and Sales Potential for Agents

BRCA1/2 Mutation Ovarian Cancer - Patient-based Market Forecast to 2035

BRCA1/2 Mutation Ovarian Cancer - Untapped Business Opportunities

BRCA1/2 Mutation Ovarian Cancer - Product Positioning Vis-a-vis Competitors' Products

BRCA1/2 Mutation Ovarian Cancer - KOLs Insight